Marksans Pharma Limited has informed the Exchange regarding a press release dated August 18, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its products.".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for three strengths of Metformin Hydrochloride Prolonged Release Tablets — 500 mg, 750 mg, and 1000 mg. Metformin is a widely used anti-diabetic generic medication. This approval allows Relonchem to manufacture and market these products in the UK, a key regulated pharmaceutical market. The approval strengthens Marksans' presence in the anti-diabetic therapeutic segment within the UK and aligns with the company's strategy of expanding its global generic formulation portfolio.
Positive for shareholders — this regulatory clearance opens a new revenue stream in the UK market and adds to Marksans' anti-diabetic portfolio, though the financial impact is not disclosed and will depend on subsequent commercial launches and market share gains.